Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LYEL
stocks logo

LYEL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
0.00
-100%
-1.830
-87.29%
0.00
-100%
-2.655
-26.25%
0.00
-100%
-2.900
+0.35%
Estimates Revision
Stock Price
Go Up
up Image
+109.55%
In Past 3 Month
Wall Street analysts forecast LYEL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LYEL is 17.33 USD with a low forecast of 12.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast LYEL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LYEL is 17.33 USD with a low forecast of 12.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
1 Sell
Hold
Current: 25.460
sliders
Low
12.00
Averages
17.33
High
20.00
Current: 25.460
sliders
Low
12.00
Averages
17.33
High
20.00
H.C. Wainwright
H.C. Wainwright
Neutral
maintain
$10 -> $20
2025-11-24
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10 -> $20
2025-11-24
maintain
Neutral
Reason
H.C. Wainwright raised the firm's price target on Lyell Immunopharma to $20 from $10 and keeps a Neutral rating on the shares. The firm added colorectal cancer to the company's valuation.
Lucid Capital
Christopher Liu
Buy
initiated
$20
2025-09-26
Reason
Lucid Capital
Christopher Liu
Price Target
$20
2025-09-26
initiated
Buy
Reason
Lucid Capital analyst Christopher Liu initiated coverage of Lyell Immunopharma with a Buy rating and $20 price target. Lyell is a clinical-stage biotechnology company focused on developing potentially curative cell therapies for cancer patients, the analyst tells investors in a research note. The firm sees peak sales of $2.2B by 2039 for the company's lead asset ronde-cel in diffuse large B-cell lymphoma. The market is competitive, but there is room for several assets in the space given the meaningfully large opportunity, contends Lucid.
H.C. Wainwright
Mitchell Kapoor
Neutral
upgrade
$1 -> $10
2025-06-24
Reason
H.C. Wainwright
Mitchell Kapoor
Price Target
$1 -> $10
2025-06-24
upgrade
Neutral
Reason
H.C. Wainwright analyst Mitchell Kapoor raised the firm's price target on Lyell Immunopharma to $10 from $1 and keeps a Neutral rating on the shares. The firm adjusted the company's model to account for the 20-for-1 reverse split earlier this month.
HC Wainwright & Co.
Mitchell Kapoor
Hold
Reiterates
$1
2025-04-16
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$1
2025-04-16
Reiterates
Hold
Reason
HC Wainwright & Co.
Mitchell Kapoor
Hold
Reiterates
$1
2025-03-13
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$1
2025-03-13
Reiterates
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Lyell Immunopharma Inc (LYEL.O) is -2.72, compared to its 5-year average forward P/E of -3.60. For a more detailed relative valuation and DCF analysis to assess Lyell Immunopharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.60
Current PE
-2.72
Overvalued PE
-0.64
Undervalued PE
-6.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.10
Undervalued EV/EBITDA
-5.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
406.91
Current PS
0.00
Overvalued PS
1713.62
Undervalued PS
-899.79
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

LYEL News & Events

Events Timeline

(ET)
2025-11-12
16:25:38
Lyell Immunopharma Announces Q3 Revenue of $15,000 Compared to $34,000 Last Year
select
2025-11-10 (ET)
2025-11-10
07:57:40
Lyell Immunopharma secures exclusive worldwide rights to LYL273
select
2025-09-03 (ET)
2025-09-03
08:09:17
Lyell Launches Phase 3 Trial for Head-to-Head CAR T-Cell Therapy
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-24Benzinga
HC Wainwright & Co. Keeps Neutral Rating on Lyell Immunopharma and Increases Price Target to $20

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.

[object Object]
Preview
4.0
09-26Benzinga
Analyst Starts Coverage on United Therapeutics with Optimism; Check Out the Top 5 Initiations for Friday

  • Analyst Coverage Initiations: Several Wall Street analysts have initiated coverage on various companies, including First Horizon Corporation, Valmont Industries, Lyell Immunopharma, Spyre Therapeutics, and United Therapeutics, with ratings ranging from Neutral to Buy and price targets set above current share prices.

  • Price Targets and Current Share Prices: The price targets announced by analysts include $24 for First Horizon, $480 for Valmont Industries, $20 for Lyell Immunopharma, $43 for Spyre Therapeutics, and $569 for United Therapeutics, with current share prices being $22.66, $364.66, $12.72, $15.61, and $425.42 respectively.

[object Object]
Preview
9.5
08-13Yahoo Finance
Lyell Immunopharma: Q2 Earnings Snapshot

  • Financial Performance: Lyell Immunopharma Inc. reported a loss of $42.7 million in the second quarter, translating to a loss of $2.89 per share.

  • Revenue Details: The biotechnology firm generated revenue of only $8,000 during the same period.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Lyell Immunopharma Inc (LYEL) stock price today?

The current price of LYEL is 25.46 USD — it has increased 14.12 % in the last trading day.

arrow icon

What is Lyell Immunopharma Inc (LYEL)'s business?

Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

arrow icon

What is the price predicton of LYEL Stock?

Wall Street analysts forecast LYEL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LYEL is 17.33 USD with a low forecast of 12.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Lyell Immunopharma Inc (LYEL)'s revenue for the last quarter?

Lyell Immunopharma Inc revenue for the last quarter amounts to 15.00K USD, decreased -55.88 % YoY.

arrow icon

What is Lyell Immunopharma Inc (LYEL)'s earnings per share (EPS) for the last quarter?

Lyell Immunopharma Inc. EPS for the last quarter amounts to -2.13 USD, decreased -38.79 % YoY.

arrow icon

What changes have occurred in the market's expectations for Lyell Immunopharma Inc (LYEL)'s fundamentals?

The market is revising No Change the revenue expectations for LYEL for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 109.55%.
arrow icon

How many employees does Lyell Immunopharma Inc (LYEL). have?

Lyell Immunopharma Inc (LYEL) has 300 emplpoyees as of December 05 2025.

arrow icon

What is Lyell Immunopharma Inc (LYEL) market cap?

Today LYEL has the market capitalization of 538.09M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free